25 XP   0   0   10

G1 Therapeutics Inc
Buy, Hold or Sell?

Let's analyse G1 Therapeutics Inc together

PenkeI guess you are interested in G1 Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of G1 Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about G1 Therapeutics Inc

I send you an email if I find something interesting about G1 Therapeutics Inc.

Quick analysis of G1 Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of G1 Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.68
Expected worth in 1 year
$0.04
How sure are you?
24.2%

+ What do you gain per year?

Total Gains per Share
$-0.64
Return On Investment
-16.0%

For what price can you sell your share?

Current Price per Share
$3.99
Expected price per share
$2.05 - $4.895
How sure are you?
50%

1. Valuation of G1 Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$3.99

Intrinsic Value Per Share

$2.21 - $3.51

Total Value Per Share

$2.89 - $4.18

2. Growth of G1 Therapeutics Inc (5 min.)




Is G1 Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$35.3m$70.2m-$25m-55.4%

How much money is G1 Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$13.2m-$38.1m$24.8m188.2%
Net Profit Margin-113.0%-394.9%--

How much money comes from the company's main activities?

3. Financial Health of G1 Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#515 / 1010

Most Revenue
#227 / 1010

Most Profit
#610 / 1010

Most Efficient
#575 / 1010

What can you expect buying and holding a share of G1 Therapeutics Inc? (5 min.)

Welcome investor! G1 Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of G1 Therapeutics Inc.

What can you expect buying and holding a share of G1 Therapeutics Inc?

First you should know what it really means to hold a share of G1 Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of G1 Therapeutics Inc is $3.99. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of G1 Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in G1 Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.68. Based on the TTM, the Book Value Change Per Share is $-0.16 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.36 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of G1 Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.21-5.2%-0.24-5.9%-0.71-17.7%-0.54-13.6%-0.48-12.0%
Usd Book Value Change Per Share-0.15-3.7%-0.16-4.0%-0.36-9.0%-0.31-7.8%0.020.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.15-3.7%-0.16-4.0%-0.36-9.0%-0.31-7.8%0.020.5%
Usd Price Per Share3.05-2.42-7.62-13.55-14.70-
Price to Earnings Ratio-3.66--0.40--3.05--5.92--7.73-
Price-to-Total Gains Ratio-20.85--2.03--9.09--25.21--37.24-
Price to Book Ratio4.50-3.00-6.54-4.53-4.68-
Price-to-Total Gains Ratio-20.85--2.03--9.09--25.21--37.24-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.99
Number of shares250
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.16-0.31
Usd Total Gains Per Share-0.16-0.31
Gains per Quarter (250 shares)-39.94-77.45
Gains per Year (250 shares)-159.78-309.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-160-1700-310-320
20-320-3300-620-630
30-479-4900-929-940
40-639-6500-1239-1250
50-799-8100-1549-1560
60-959-9700-1859-1870
70-1118-11300-2169-2180
80-1278-12900-2478-2490
90-1438-14500-2788-2800
100-1598-16100-3098-3110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.032.00.03.0%1.032.00.03.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%3.017.00.015.0%8.022.03.024.2%8.022.03.024.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.033.00.0%0.00.033.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%3.017.00.015.0%8.022.03.024.2%8.022.03.024.2%

Fundamentals of G1 Therapeutics Inc

About G1 Therapeutics Inc

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Fundamental data was last updated by Penke on 2024-04-11 10:26:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of G1 Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit G1 Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare G1 Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -73.1% means that $-0.73 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of G1 Therapeutics Inc:

  • The MRQ is -73.1%. The company is making a huge loss. -2
  • The TTM is -113.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-73.1%TTM-113.0%+39.8%
TTM-113.0%YOY-394.9%+282.0%
TTM-113.0%5Y-301.7%+188.8%
5Y-301.7%10Y-300.5%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-73.1%-200.1%+127.0%
TTM-113.0%-216.8%+103.8%
YOY-394.9%-288.3%-106.6%
5Y-301.7%-449.1%+147.4%
10Y-300.5%-605.5%+305.0%
1.1.2. Return on Assets

Shows how efficient G1 Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare G1 Therapeutics Inc to the Biotechnology industry mean.
  • -9.0% Return on Assets means that G1 Therapeutics Inc generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of G1 Therapeutics Inc:

  • The MRQ is -9.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.0%TTM-9.2%+0.3%
TTM-9.2%YOY-19.8%+10.6%
TTM-9.2%5Y-12.5%+3.3%
5Y-12.5%10Y-16.5%+4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.0%-13.3%+4.3%
TTM-9.2%-12.8%+3.6%
YOY-19.8%-11.7%-8.1%
5Y-12.5%-13.9%+1.4%
10Y-16.5%-15.7%-0.8%
1.1.3. Return on Equity

Shows how efficient G1 Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare G1 Therapeutics Inc to the Biotechnology industry mean.
  • -30.7% Return on Equity means G1 Therapeutics Inc generated $-0.31 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of G1 Therapeutics Inc:

  • The MRQ is -30.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -32.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.7%TTM-32.6%+1.8%
TTM-32.6%YOY-54.7%+22.1%
TTM-32.6%5Y-26.0%-6.5%
5Y-26.0%10Y-25.7%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.7%-16.9%-13.8%
TTM-32.6%-16.1%-16.5%
YOY-54.7%-15.1%-39.6%
5Y-26.0%-19.3%-6.7%
10Y-25.7%-20.2%-5.5%

1.2. Operating Efficiency of G1 Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient G1 Therapeutics Inc is operating .

  • Measures how much profit G1 Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare G1 Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -60.0% means the company generated $-0.60  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of G1 Therapeutics Inc:

  • The MRQ is -60.0%. The company is operating very inefficient. -2
  • The TTM is -90.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-60.0%TTM-90.7%+30.7%
TTM-90.7%YOY-355.0%+264.3%
TTM-90.7%5Y-283.7%+192.9%
5Y-283.7%10Y-261.5%-22.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-60.0%-296.2%+236.2%
TTM-90.7%-232.5%+141.8%
YOY-355.0%-298.2%-56.8%
5Y-283.7%-492.1%+208.4%
10Y-261.5%-632.4%+370.9%
1.2.2. Operating Ratio

Measures how efficient G1 Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.60 means that the operating costs are $1.60 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of G1 Therapeutics Inc:

  • The MRQ is 1.600. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.975. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.600TTM1.975-0.374
TTM1.975YOY4.550-2.576
TTM1.9755Y3.593-1.618
5Y3.59310Y4.026-0.434
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6003.231-1.631
TTM1.9753.310-1.335
YOY4.5503.890+0.660
5Y3.5935.739-2.146
10Y4.0267.876-3.850

1.3. Liquidity of G1 Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if G1 Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.87 means the company has $3.87 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of G1 Therapeutics Inc:

  • The MRQ is 3.868. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.082. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.868TTM4.082-0.213
TTM4.082YOY4.998-0.917
TTM4.0825Y9.658-5.576
5Y9.65810Y10.253-0.594
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8683.890-0.022
TTM4.0824.173-0.091
YOY4.9985.344-0.346
5Y9.6586.126+3.532
10Y10.2536.448+3.805
1.3.2. Quick Ratio

Measures if G1 Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare G1 Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.87 means the company can pay off $4.87 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of G1 Therapeutics Inc:

  • The MRQ is 4.874. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.859. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.874TTM4.859+0.015
TTM4.859YOY4.951-0.093
TTM4.8595Y9.615-4.756
5Y9.61510Y9.868-0.253
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8743.514+1.360
TTM4.8593.998+0.861
YOY4.9515.380-0.429
5Y9.6156.105+3.510
10Y9.8686.404+3.464

1.4. Solvency of G1 Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of G1 Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare G1 Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.71 means that G1 Therapeutics Inc assets are financed with 70.9% credit (debt) and the remaining percentage (100% - 70.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of G1 Therapeutics Inc:

  • The MRQ is 0.709. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.680. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.709TTM0.680+0.029
TTM0.680YOY0.636+0.044
TTM0.6805Y0.373+0.307
5Y0.37310Y0.262+0.111
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7090.339+0.370
TTM0.6800.336+0.344
YOY0.6360.271+0.365
5Y0.3730.366+0.007
10Y0.2620.389-0.127
1.4.2. Debt to Equity Ratio

Measures if G1 Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare G1 Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 243.5% means that company has $2.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of G1 Therapeutics Inc:

  • The MRQ is 2.435. The company is just not able to pay all its debts with equity.
  • The TTM is 2.175. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.435TTM2.175+0.260
TTM2.175YOY1.839+0.336
TTM2.1755Y0.951+1.223
5Y0.95110Y0.617+0.335
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4350.388+2.047
TTM2.1750.402+1.773
YOY1.8390.335+1.504
5Y0.9510.426+0.525
10Y0.6170.461+0.156

2. Market Valuation of G1 Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings G1 Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare G1 Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -3.66 means the investor is paying $-3.66 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of G1 Therapeutics Inc:

  • The EOD is -4.787. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.659. Based on the earnings, the company is expensive. -2
  • The TTM is -0.399. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.787MRQ-3.659-1.128
MRQ-3.659TTM-0.399-3.260
TTM-0.399YOY-3.051+2.652
TTM-0.3995Y-5.917+5.518
5Y-5.91710Y-7.730+1.813
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.787-2.264-2.523
MRQ-3.659-2.629-1.030
TTM-0.399-2.680+2.281
YOY-3.051-4.145+1.094
5Y-5.917-6.257+0.340
10Y-7.730-6.254-1.476
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of G1 Therapeutics Inc:

  • The EOD is -4.070. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.111. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.849. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.070MRQ-3.111-0.959
MRQ-3.111TTM-0.849-2.263
TTM-0.849YOY-3.558+2.710
TTM-0.8495Y-3.907+3.058
5Y-3.90710Y-7.445+3.538
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.070-2.973-1.097
MRQ-3.111-3.333+0.222
TTM-0.849-3.553+2.704
YOY-3.558-5.605+2.047
5Y-3.907-8.376+4.469
10Y-7.445-8.865+1.420
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of G1 Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.50 means the investor is paying $4.50 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of G1 Therapeutics Inc:

  • The EOD is 5.886. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.499. Based on the equity, the company is fair priced.
  • The TTM is 2.999. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.886MRQ4.499+1.387
MRQ4.499TTM2.999+1.500
TTM2.999YOY6.539-3.540
TTM2.9995Y4.529-1.530
5Y4.52910Y4.677-0.148
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.8861.896+3.990
MRQ4.4992.115+2.384
TTM2.9992.093+0.906
YOY6.5392.884+3.655
5Y4.5293.542+0.987
10Y4.6773.916+0.761
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of G1 Therapeutics Inc.

3.1. Institutions holding G1 Therapeutics Inc

Institutions are holding 30.179% of the shares of G1 Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc3.79640.00011981673316051.6207
2023-12-31Susquehanna International Group, LLP3.02420.0009157860115786010
2023-12-31BlackRock Inc1.3040.0001680664-439643-39.2431
2023-12-31Renaissance Technologies Corp1.20770.00363040015632032.9733
2023-09-30Jacobs Levy Equity Management, Inc.1.09820.00495732568048016.332
2023-12-31Raymond James & Associates1.08350.0013565555-360221-38.9102
2023-12-31Group One Trading, LP0.99870.00425213274745161013.6848
2023-09-30D. E. Shaw & Co LP0.96760.0008505082-111421-18.0731
2023-12-31Geode Capital Management, LLC0.88270.0002460775201424.5712
2023-12-31abrdn PLC0.8120.00284238694238690
2023-12-31Marshall Wace Asset Management Ltd0.69020.0019360293-156435-30.2741
2023-12-31Bank of America Corp0.53540.0001279459-8806-3.0548
2023-12-31SIMPLEX TRADING, LLC0.44760.00052336262161461236.5332
2023-12-31Connor Clark & Lunn Inv Mgmt Ltd0.3680.0027192110-12090-5.9207
2023-12-31Needham Investment Management, LLC0.34480.0693180000-54000-23.0769
2023-12-31Level Four Advisory Services, LLC0.34210.0306178600-4800-2.6172
2023-12-31Morgan Stanley - Brokerage Accounts0.32580.0001170058134915383.9029
2023-12-31Two Sigma Investments LLC0.31050.00111620637166379.2732
2023-12-31State Street Corporation0.3086016110600
2023-12-31XTX Topco Ltd0.30120.105157201-139400-46.9992
Total 19.14920.22969995718+1901441+19.0%

3.2. Funds holding G1 Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.65290.0003138480200
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.19820.002625460106001.724
2024-02-29Fidelity Extended Market Index0.46740.0021243982-1182-0.4821
2024-02-29abrdn Life Sciences Investors0.42790.167722337700
2024-02-29abrdn Healthcare Investors0.38410.066420049200
2023-09-30BlackRock Extended Mkt Composite0.26860.001414018900
2023-12-31Bridgeway Ultra-Small Company Market0.22990.197120000-20000-14.2857
2024-03-28iShares Micro-Cap ETF0.2030.049810595100
2024-03-31BlackRock Extended Equity Market K0.16740.002687360310.0355
2024-02-29Fidelity Total Market Index0.15340.00038008800
2023-12-31Needham Aggressive Growth Retail0.13410.05387000000
2024-02-29Fidelity Series Total Market Index0.11320.00035908500
2023-12-31LUNIS Biotech Growth Opp Fd I a0.10155.57555300000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.09710.0025506622124272.2026
2024-02-29Onelife Fund USD0.0780.44194070000
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.07790.0025406891710572.528
2023-12-31Northern Trust Extended Eq Market Idx0.07590.002139605496914.3463
2023-12-31NT Ext Equity Mkt Idx Fd - L0.07590.002139605496914.3463
2024-02-29Vifag 2002 SICAV0.06890.18653594000
2023-12-31Needham Growth Retail0.06710.072535000-29000-45.3125
Total 7.04246.82933675987+8734+0.2%

3.3. Insider Transactions

Insiders are holding 11.678% of the shares of G1 Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-18John W V UmsteadSELL65473.02
2024-02-12Rajesh MalikSELL286004.62
2024-01-04John W V UmsteadSELL1112.94
2024-01-04Terry L MurdockSELL7212.94
2024-01-03Rajesh MalikSELL30193.12
2024-01-02John E (jack) Jr. BaileySELL329833.27
2023-12-11Rajesh MalikSELL338393.41
2023-07-05Andrew PerrySELL3552.45
2023-07-05John E (jack) Jr. BaileySELL27192.45
2023-07-05Terry L MurdockSELL13612.45

4. Summary

4.1. Key Performance Indicators

The key performance indicators of G1 Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.146-0.160+9%-0.358+145%-0.310+112%0.021-812%
Book Value Per Share--0.6780.827-18%1.347-50%3.099-78%2.798-76%
Current Ratio--3.8684.082-5%4.998-23%9.658-60%10.253-62%
Debt To Asset Ratio--0.7090.680+4%0.636+11%0.373+90%0.262+171%
Debt To Equity Ratio--2.4352.175+12%1.839+32%0.951+156%0.617+295%
Dividend Per Share----0%-0%-0%-0%
Eps---0.208-0.236+13%-0.707+239%-0.543+161%-0.477+129%
Free Cash Flow Per Share---0.245-0.193-21%-0.618+152%-0.467+91%-0.379+55%
Free Cash Flow To Equity Per Share---0.244-0.304+24%-0.366+50%-0.276+13%0.045-641%
Gross Profit Margin--1.0001.0000%1.0000%1.0010%1.0010%
Intrinsic Value_10Y_max--3.507--------
Intrinsic Value_10Y_min--2.207--------
Intrinsic Value_1Y_max---1.599--------
Intrinsic Value_1Y_min---1.571--------
Intrinsic Value_3Y_max---3.317--------
Intrinsic Value_3Y_min---3.197--------
Intrinsic Value_5Y_max---3.244--------
Intrinsic Value_5Y_min---3.139--------
Market Cap208275606.000+24%159208170.000131565140.108+21%397498431.000-60%708506986.622-78%768093189.710-79%
Net Profit Margin---0.731-1.130+54%-3.949+440%-3.017+313%-3.005+311%
Operating Margin---0.600-0.907+51%-3.550+491%-2.837+373%-2.615+336%
Operating Ratio--1.6001.975-19%4.550-65%3.593-55%4.026-60%
Pb Ratio5.886+24%4.4992.999+50%6.539-31%4.529-1%4.677-4%
Pe Ratio-4.787-31%-3.659-0.399-89%-3.051-17%-5.917+62%-7.730+111%
Price Per Share3.990+24%3.0502.415+26%7.615-60%13.552-77%14.702-79%
Price To Free Cash Flow Ratio-4.070-31%-3.111-0.849-73%-3.558+14%-3.907+26%-7.445+139%
Price To Total Gains Ratio-27.275-31%-20.850-2.029-90%-9.087-56%-25.206+21%-37.235+79%
Quick Ratio--4.8744.859+0%4.951-2%9.615-49%9.868-51%
Return On Assets---0.090-0.092+3%-0.198+121%-0.125+40%-0.165+85%
Return On Equity---0.307-0.326+6%-0.547+78%-0.260-15%-0.257-16%
Total Gains Per Share---0.146-0.160+9%-0.358+145%-0.310+112%0.021-812%
Usd Book Value--35386000.00045236000.000-22%70292250.000-50%162200350.000-78%146317415.939-76%
Usd Book Value Change Per Share---0.146-0.160+9%-0.358+145%-0.310+112%0.021-812%
Usd Book Value Per Share--0.6780.827-18%1.347-50%3.099-78%2.798-76%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.208-0.236+13%-0.707+239%-0.543+161%-0.477+129%
Usd Free Cash Flow---12792000.000-9584250.000-25%-32281500.000+152%-24280000.000+90%-19719742.455+54%
Usd Free Cash Flow Per Share---0.245-0.193-21%-0.618+152%-0.467+91%-0.379+55%
Usd Free Cash Flow To Equity Per Share---0.244-0.304+24%-0.366+50%-0.276+13%0.045-641%
Usd Market Cap208275606.000+24%159208170.000131565140.108+21%397498431.000-60%708506986.622-78%768093189.710-79%
Usd Price Per Share3.990+24%3.0502.415+26%7.615-60%13.552-77%14.702-79%
Usd Profit---10878000.000-13226250.000+22%-38113500.000+250%-28770600.000+164%-23375007.545+115%
Usd Revenue--14873000.00020627750.000-28%12825250.000+16%10528650.000+41%6396818.182+133%
Usd Total Gains Per Share---0.146-0.160+9%-0.358+145%-0.310+112%0.021-812%
 EOD+5 -3MRQTTM+20 -13YOY+21 -125Y+20 -1410Y+14 -20

4.2. Fundamental Score

Let's check the fundamental score of G1 Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.787
Price to Book Ratio (EOD)Between0-15.886
Net Profit Margin (MRQ)Greater than0-0.731
Operating Margin (MRQ)Greater than0-0.600
Quick Ratio (MRQ)Greater than14.874
Current Ratio (MRQ)Greater than13.868
Debt to Asset Ratio (MRQ)Less than10.709
Debt to Equity Ratio (MRQ)Less than12.435
Return on Equity (MRQ)Greater than0.15-0.307
Return on Assets (MRQ)Greater than0.05-0.090
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of G1 Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.561
Ma 20Greater thanMa 504.438
Ma 50Greater thanMa 1003.648
Ma 100Greater thanMa 2003.504
OpenGreater thanClose4.190
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets121,540
Total Liabilities86,154
Total Stockholder Equity35,386
 As reported
Total Liabilities 86,154
Total Stockholder Equity+ 35,386
Total Assets = 121,540

Assets

Total Assets121,540
Total Current Assets114,948
Long-term Assets6,592
Total Current Assets
Cash And Cash Equivalents 32,281
Short-term Investments 49,938
Net Receivables 12,687
Inventory 12,442
Other Current Assets 7,600
Total Current Assets  (as reported)114,948
Total Current Assets  (calculated)114,948
+/-0
Long-term Assets
Property Plant Equipment 6,384
Long-term Assets Other 21
Long-term Assets  (as reported)6,592
Long-term Assets  (calculated)6,405
+/- 187

Liabilities & Shareholders' Equity

Total Current Liabilities29,716
Long-term Liabilities56,438
Total Stockholder Equity35,386
Total Current Liabilities
Short-term Debt 1,276
Accounts payable 3,992
Other Current Liabilities 23,828
Total Current Liabilities  (as reported)29,716
Total Current Liabilities  (calculated)29,096
+/- 620
Long-term Liabilities
Long term Debt 51,557
Capital Lease Obligations 4,340
Long-term Liabilities Other 41
Long-term Liabilities  (as reported)56,438
Long-term Liabilities  (calculated)55,938
+/- 500
Total Stockholder Equity
Common Stock5
Retained Earnings -779,985
Other Stockholders Equity 815,366
Total Stockholder Equity (as reported)35,386
Total Stockholder Equity (calculated)35,386
+/-0
Other
Capital Stock5
Cash and Short Term Investments 82,219
Common Stock Shares Outstanding 51,839
Current Deferred Revenue620
Liabilities and Stockholders Equity 121,540
Net Debt 24,892
Net Invested Capital 86,943
Net Working Capital 85,232
Property Plant and Equipment Gross 8,723
Short Long Term Debt Total 57,173



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-31
> Total Assets 
23,897
0
0
0
48,212
39,294
134,101
119,551
105,171
195,741
190,600
393,019
371,270
351,675
331,653
317,186
284,831
256,514
253,597
258,232
228,552
308,558
276,755
243,497
254,094
218,239
186,879
166,573
187,965
161,957
147,891
133,097
121,540
121,540133,097147,891161,957187,965166,573186,879218,239254,094243,497276,755308,558228,552258,232253,597256,514284,831317,186331,653351,675371,270393,019190,600195,741105,171119,551134,10139,29448,21200023,897
   > Total Current Assets 
23,750
22,938
0
0
47,901
38,982
133,768
119,035
104,661
195,183
189,889
392,013
370,133
348,884
328,277
302,980
271,003
243,589
240,091
245,594
216,392
297,012
265,700
232,983
243,565
208,336
177,100
157,465
179,500
153,965
140,436
126,103
114,948
114,948126,103140,436153,965179,500157,465177,100208,336243,565232,983265,700297,012216,392245,594240,091243,589271,003302,980328,277348,884370,133392,013189,889195,183104,661119,035133,76838,98247,9010022,93823,750
       Cash And Cash Equivalents 
22,938
-22,938
0
0
47,305
37,727
132,675
118,380
103,812
194,387
188,227
390,524
369,290
347,797
324,911
299,933
269,208
242,402
234,267
238,342
207,306
278,968
244,023
212,089
221,186
183,020
143,957
93,238
94,594
116,317
55,914
94,352
32,281
32,28194,35255,914116,31794,59493,238143,957183,020221,186212,089244,023278,968207,306238,342234,267242,402269,208299,933324,911347,797369,290390,524188,227194,387103,812118,380132,67537,72747,30500-22,93822,938
       Short-term Investments 
0
45,875
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29,744
50,476
48,080
48,317
41,729
49,938
49,93841,72948,31748,08050,47629,744000000000000000000000000045,8750
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
237
5,048
4,962
5,240
5,688
7,615
10,787
10,521
11,094
16,025
13,171
9,265
12,687
12,6879,26513,17116,02511,09410,52110,7877,6155,6885,2404,9625,04823700000000000000000000
       Other Current Assets 
812
0
0
0
596
1,256
1,093
655
849
796
1,662
1,489
843
1,087
3,366
3,047
1,795
1,187
5,824
7,252
8,849
11,569
15,313
14,279
13,220
9,841
8,342
10,012
7,094
6,080
7,371
8,995
7,600
7,6008,9957,3716,0807,09410,0128,3429,84113,22014,27915,31311,5698,8497,2525,8241,1871,7953,0473,3661,0878431,4891,6627968496551,0931,256596000812
   > Long-term Assets 
0
0
0
0
311
312
333
516
510
558
711
1,006
1,137
2,791
3,376
14,206
13,828
12,925
13,506
12,638
12,160
11,546
11,055
10,514
10,529
9,903
9,779
9,108
8,465
7,992
7,455
6,994
6,592
6,5926,9947,4557,9928,4659,1089,7799,90310,52910,51411,05511,54612,16012,63813,50612,92513,82814,2063,3762,7911,1371,0067115585105163333123110000
       Property Plant Equipment 
147
0
0
0
311
312
333
516
510
558
711
1,006
1,137
2,791
2,876
13,769
13,391
12,488
11,708
10,883
10,508
10,148
9,784
9,417
9,048
8,673
8,773
8,365
7,951
7,564
7,173
6,780
6,384
6,3846,7807,1737,5647,9518,3658,7738,6739,0489,4179,78410,14810,50810,88311,70812,48813,39113,7692,8762,7911,1371,006711558510516333312311000147
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
437
437
437
1,798
1,755
9,678
1,398
1,271
1,097
1,481
1,230
1,006
743
514
0
282
0
0
0028205147431,0061,2301,4811,0971,2711,3989,6781,7551,79843743743750000000000000000
> Total Liabilities 
2,167
0
0
0
5,625
8,296
10,410
10,421
11,783
12,586
14,076
13,764
12,450
12,734
18,983
31,067
29,304
27,064
49,752
60,760
51,201
63,115
63,559
65,158
110,553
118,107
120,554
120,608
119,218
116,969
90,343
90,075
86,154
86,15490,07590,343116,969119,218120,608120,554118,107110,55365,15863,55963,11551,20160,76049,75227,06429,30431,06718,98312,73412,45013,76414,07612,58611,78310,42110,4108,2965,6250002,167
   > Total Current Liabilities 
2,167
0
0
0
5,625
8,296
10,410
10,421
11,704
12,507
13,997
13,674
12,362
11,549
17,893
21,222
19,769
18,448
21,924
32,959
23,443
25,604
25,641
26,839
27,613
34,983
37,252
37,134
35,588
33,690
33,912
33,653
29,716
29,71633,65333,91233,69035,58837,13437,25234,98327,61326,83925,64125,60423,44332,95921,92418,44819,76921,22217,89311,54912,36213,67413,99712,50711,70410,42110,4108,2965,6250002,167
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
361
369
472
682
0
0
15,662
16,486
18,075
18,566
22,013
1,115
0
0
0
1,135
0
24,681
0
1,276
1,276024,68101,1350001,11522,01318,56618,07516,48615,662006824723693610000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
361
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000003610000000000000
       Accounts payable 
1,128
0
0
0
2,605
3,667
5,132
4,234
4,184
3,872
3,311
2,752
3,377
3,076
3,292
7,236
3,684
4,703
2,816
2,309
3,572
4,783
3,638
3,577
2,897
11,018
9,349
8,442
7,431
5,380
5,762
7,335
3,992
3,9927,3355,7625,3807,4318,4429,34911,0182,8973,5773,6384,7833,5722,3092,8164,7033,6847,2363,2923,0763,3772,7523,3113,8724,1844,2345,1323,6672,6050001,128
       Other Current Liabilities 
1,039
0
0
0
3,021
4,629
5,278
6,187
7,520
8,635
10,686
10,922
8,985
361
14,232
13,514
15,403
13,745
19,108
957
3,148
2,592
3,252
1,223
23,570
23,948
27,893
28,683
27,015
27,805
3,326
25,632
23,828
23,82825,6323,32627,80527,01528,68327,89323,94823,5701,2233,2522,5923,14895719,10813,74515,40313,51414,2323618,98510,92210,6868,6357,5206,1875,2784,6293,0210001,039
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
79
79
79
90
88
1,185
1,090
9,845
9,535
8,616
27,828
27,801
27,758
37,511
37,918
38,319
82,940
83,124
83,302
83,474
83,630
83,279
56,431
56,422
56,438
56,43856,42256,43183,27983,63083,47483,30283,12482,94038,31937,91837,51127,75827,80127,8288,6169,5359,8451,0901,185889079797900000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,453
19,673
19,893
29,913
30,093
30,273
75,190
75,646
76,102
76,558
77,015
77,470
50,936
0
0
0050,93677,47077,01576,55876,10275,64675,19030,27330,09329,91319,89319,67319,453000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
79
79
79
90
88
0
0
0
0
0
0
0
0
0
500
1,000
1,000
1,000
1,000
1,000
1,000
0
500
0
0
0050001,0001,0001,0001,0001,0001,000500000000000889079797900000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
1,000
1,000
1,000
1,000
1,000
1,000
500
500
0
0
005005001,0001,0001,0001,0001,0001,0005000000000000000000000000
> Total Stockholder Equity
21,730
21,729
0
0
42,587
30,998
123,691
109,130
93,388
183,155
176,524
379,255
358,820
338,941
312,670
286,119
255,527
229,450
203,845
197,472
177,351
245,443
213,196
178,339
143,541
100,132
66,325
45,965
68,747
44,988
57,548
43,022
35,386
35,38643,02257,54844,98868,74745,96566,325100,132143,541178,339213,196245,443177,351197,472203,845229,450255,527286,119312,670338,941358,820379,255176,524183,15593,388109,130123,69130,99842,5870021,72921,730
   Common Stock
0
0
0
0
0
2
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
555554444444444444444433333200000
   Retained Earnings Total Equity00-750,903-759,613-732,018-698,369-673,097-633,651-584,459-544,439-501,971-462,549-436,107-410,760-399,086-367,876-336,853-301,412-269,048-238,358-214,406-190,315-170,397-149,528-129,118-112,137-96,536000000
   Accumulated Other Comprehensive Income 0000000000-1,065-9470-708-991-836-677-535-449-386-322-265-239-213-181-151-139-120-1070000
   Capital Surplus 
0
0
0
0
0
0
220,232
221,272
222,511
332,688
346,926
569,574
573,230
577,303
581,722
587,535
592,384
597,330
602,935
608,236
613,462
707,996
715,171
722,782
728,004
733,787
739,426
744,338
800,768
804,604
808,454
0
0
00808,454804,604800,768744,338739,426733,787728,004722,782715,171707,996613,462608,236602,935597,330592,384587,535581,722577,303573,230569,574346,926332,688222,511221,272220,232000000
   Treasury Stock00000-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8000-8
   Other Stockholders Equity 
0
-31,695
0
0
99
112,366
220,363
221,415
222,684
332,893
347,157
569,831
573,544
577,681
582,163
588,062
593,053
598,158
603,918
608,936
-4
708,935
716,228
722,774
-4
733,779
739,418
744,330
800,760
-5
808,446
-5
815,366
815,366-5808,446-5800,760744,330739,418733,779-4722,774716,228708,935-4608,936603,918598,158593,053588,062582,163577,681573,544569,831347,157332,893222,684221,415220,363112,3669900-31,6950



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue82,511
Cost of Revenue-7,195
Gross Profit75,31675,316
 
Operating Income (+$)
Gross Profit75,316
Operating Expense-114,843
Operating Income-39,527-39,527
 
Operating Expense (+$)
Research Development43,711
Selling General Administrative79,524
Selling And Marketing Expenses0
Operating Expense114,843123,235
 
Net Interest Income (+$)
Interest Income2,422
Interest Expense-10,038
Other Finance Cost-872
Net Interest Income-8,488
 
Pretax Income (+$)
Operating Income-39,527
Net Interest Income-8,488
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-44,852-34,202
EBIT - interestExpense = -49,565
-44,852
-37,929
Interest Expense10,038
Earnings Before Interest and Taxes (EBIT)-39,527-34,814
Earnings Before Interest and Taxes (EBITDA)-39,014
 
After tax Income (+$)
Income Before Tax-44,852
Tax Provision-2,694
Net Income From Continuing Ops-70,738-47,546
Net Income-47,967
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses122,038
Total Other Income/Expenses Net-5,3258,488
 

Technical Analysis of G1 Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of G1 Therapeutics Inc. The general trend of G1 Therapeutics Inc is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine G1 Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of G1 Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.85 < 4.875 < 4.895.

The bearish price targets are: 3.87 > 2.933 > 2.05.

Tweet this
G1 Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of G1 Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

G1 Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of G1 Therapeutics Inc. The current macd is 0.06711102.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the G1 Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for G1 Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the G1 Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
G1 Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartG1 Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of G1 Therapeutics Inc. The current adx is 19.66.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell G1 Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
G1 Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of G1 Therapeutics Inc. The current sar is 4.51627748.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
G1 Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of G1 Therapeutics Inc. The current rsi is 45.56. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
G1 Therapeutics Inc Daily Relative Strength Index (RSI) ChartG1 Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of G1 Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the G1 Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
G1 Therapeutics Inc Daily Stochastic Oscillator ChartG1 Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of G1 Therapeutics Inc. The current cci is -121.36113548.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
G1 Therapeutics Inc Daily Commodity Channel Index (CCI) ChartG1 Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of G1 Therapeutics Inc. The current cmo is -22.81991294.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
G1 Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartG1 Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of G1 Therapeutics Inc. The current willr is -94.76439791.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
G1 Therapeutics Inc Daily Williams %R ChartG1 Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of G1 Therapeutics Inc.

G1 Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of G1 Therapeutics Inc. The current atr is 0.32828273.

G1 Therapeutics Inc Daily Average True Range (ATR) ChartG1 Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of G1 Therapeutics Inc. The current obv is 14,164,828.

G1 Therapeutics Inc Daily On-Balance Volume (OBV) ChartG1 Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of G1 Therapeutics Inc. The current mfi is 35.90.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
G1 Therapeutics Inc Daily Money Flow Index (MFI) ChartG1 Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for G1 Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

G1 Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of G1 Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.561
Ma 20Greater thanMa 504.438
Ma 50Greater thanMa 1003.648
Ma 100Greater thanMa 2003.504
OpenGreater thanClose4.190
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of G1 Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on G1 Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about G1 Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about G1 Therapeutics Inc

I send you an email if I find something interesting about G1 Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about G1 Therapeutics Inc.

Receive notifications about G1 Therapeutics Inc in your mailbox!